Germline genetic testing for pathogenic variants (PVs) in cancer susceptibility genes after breast cancer diagnosis may inform cancer treatment, prevention, and testing of relatives. Whether testing should be performed depends partly on PV prevalence, which may be low in the general population but higher in women with risk factors (eg, young diagnosis age, family history). For the best-characterized breast cancer susceptibility genes, BRCA1, BRCA2, or both (BRCA1/2), a minimum PV prevalence of 2.5% to 10% has been recommended for testing.1 However, guidelines vary in testing all breast cancer patients2 vs only those with features suggestive of hereditary risk.3 Most guidelines do not address testing among postmenopausal women without hereditary risk factors, the most common subgroup of breast cancer patients, as PV prevalence data are lacking. This study’s purpose was to determine PV prevalence among women diagnosed with breast cancer after menopause vs the background prevalence among cancer-free postmenopausal women.

more info : https://jamanetwork.com/journals/jama/article-abstract/2762602

Subscribirse al Directorio
Escribir un Artículo

Últimas Noticias

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Destacadas

Entrevista con Dámaso Molero, director ...

by 3P Biopharmaceuticals

Dámaso Molero:" Creo que en Latinoamérica habrá negocio en el d...

Advierten de riesgos evitables en ancian...

by Agencia Sinc

Expertos del Centro de Farmacovigilancia de Castilla y León, ubicado ...

Diapositiva de Fotos